CannabisNewsWire
Editorial Coverage: Cannabis companies are seeing substantial
growth, with the popularity of cannabidiol (CBD) playing a
significant part in their positive outlook.
- CBD is an active ingredient in cannabis.
- It can provide health benefits without the psychotropic effects
of other cannabis chemicals.
- This has led to a growth in companies selling CBD treatments,
sometimes alongside more conventional wellness products.
Youngevity International, Inc. (NASDAQ: YGYI) (YGYI
Profile) is one of these companies, having recently
expanded its range of products to include CBD therapies for muscle
pain, sleeplessness and mood improvement. GW
Pharmaceuticals Plc (NASDAQ: GWPH) has created a CBD
treatment for child-onset epilepsy and received approval from the
U.S. Food and Drug Administration for its sale as a medicinal
product. Tilray, Inc. (NASDAQ: TLRY) has also
developed a cannabis-derived epilepsy treatment, even as it makes
deals to expand its distribution network in Canada. Aphria,
Inc. (OTC: APHQF) (TSX: APH) has seen a steady rise in
profits based on its cannabis work and is now working with branding
specialists to capitalize on its opportunities. Isodiol
International, Inc. (OTC: ISOLF) (CSE: ISOL) is providing
not only a range of CBD products but also a platform for patients
to connect with doctors to help manage cannabis-based medical
treatment.
Cannabis Growth Continues
The past few years have seen substantial growth in the cannabis
industry. As the plant’s legalization spreads, an increasingly
diverse range of businesses have appeared to fill the needs of a
growing wellness market. From hydroponic supply companies to seed
providers, the industry is expanding at a rapid pace, and at its
heart are the cannabis companies themselves, several of which have seen their stocks soar.
One of the reasons for recent growth is the development of a
market in cannabidiol (CBD)
drugs and wellness products. One of the active ingredients in
cannabis, CBD is being used in a wide range of treatments to help
with everything from epilepsy to mental alertness. A growing body
of research and increasing range of uses have seen CBD oil become a
significant part of the cannabis market, distinct from recreational
marijuana. For companies invested in CBD, this trend is providing a
fresh surge of growth.
The Power of Cannabidiol
A growing number of companies are producing and supplying CBD
products — not just specialist firms, but other suppliers such as
lifestyle company Youngevity
International, Inc. (NASDAQ: YGYI). So what’s the fuss
about?
CBD is one of the most prominent active ingredients in cannabis
plants. Unlike tetrahydrocannabinol (THC), CBD does not cause users
to get high, but it can have other effects on the body and mind.
Those beneficial effects have led to CBD’s rising popularity for
use in a variety of medicines and wellness products as researchers
have learned more about it.
The distinction between CBD and THC is an important one. In some
jurisdictions, industrial hemp, a type of cannabis plant that
includes CBD but non-noteworthy amounts of THC, can be grown in
circumstances where marijuana can’t. The legality of CBD products
is different from that of cannabis cultivation itself in some
places. Even in places where cannabis is legal for both medical and
recreational uses, CBD is preferable to many health-conscious
consumers who want its health effects without getting high.
It’s this potential that has drawn companies such as Youngevity
to CBD. This market is expected to see tremendous growth based on
forecasts for a range of uses beyond oils, such as CBD’s inclusion
in food, drink, cosmetics and emerging health products. That’s a
pretty impressive reason for companies to take an interest in CBD,
whether they’re experienced cannabis insiders or newcomers such as
Youngevity.
Wider Market Growth
Medical cannabis is now legal in more than half of North
America. Legal recreational use has been enacted within nine states
and the District of Columbia in the United States, and it will
premiere nationwide in Canada in October. The cannabis plant’s
ardent fan base is increasing public awareness and a growing
acceptance of the potential benefits of products derived from it.
Companies are moving to make the most of the opportunity as a
previously frowned-on and illegal industry shifts into the
mainstream.
This means that Youngevity’s cannabis-derived products will
benefit from a wave of public awareness, publicity and market
growth. The global value of this market was estimated at $7.7
billion in 2017, and it’s been predicted to reach
$34.1 billion by 2021.
That growing market means that there’s now space for CBD
products both on the shelves of high street stores and in the
inventory of companies such as Youngevity.
Youngevity’s first entry into this market is the HempFX™ product
line, introduced at the company’s 2018 convention in San Diego,
Calif. A set of three distinct hemp-derived CBD oil products under
the HempFX banner use organically grown products in proprietary
formulas to help users through their day. The products include
Soothe™, a blend of botanicals designed to relieve muscles by
calming aches and pains; Uplift™, which combines CBD with St.
John’s Wort to improve cognitive performance and mood; and Relax™,
which combines CBD with a variety of herbs and melatonin to bring
relaxation and a better night’s sleep.
This diverse range of uses shows why CBD is becoming so popular.
By applying it to a variety of wellness issues, companies are able
to market their products to a broad range of consumers, increasing
sales and awareness.
Youngevity CEO Steve Wallach highlighted the strong potential
link between CBD and broader trends in healthy living. “We firmly
believe in plant-based nutrition, and hemp-derived (CBD) oil
perfectly complements our product development philosophy. Entering
this market, which is growing almost exponentially, also should
offer a tremendous advantage to our many distributors around the
world,” he stated in the company’s news release announcing the
HempFX line.
The Power of Existing Pipelines
Wallach’s reference to distributors highlights why a company
such as Youngevity is so well-positioned to benefit from the surge
in CBD. New companies set up to cater to the CBD market have to
build their sales pipelines from scratch, whereas established
operators already have those pipelines in place. Youngevity’s
massive network of direct sellers means that it has an immediate
way of getting new products into the hands of consumers. Experience
derived from 21 years of development has provided the company with
the tools it needs to carve out its place in the market.
Being on-brand is important to such a move. Not just any company
can jump into CBD and expect customers and distributors to come
along with it. But according to Wallach, this isn’t a problem for
Youngevity.
“Hemp-derived cannabidiol aligns with what we do very well,” he
stated. “We’ve taken what we know about essential nutrients, along
with decades of knowledge specializing in natural, plant-based
nutrition and their most beneficial nutrients, and put that
knowledge to work to develop high-end cannabidiol products.”
More Companies Take Up CBD
While CBD is often used in over-the-counter medicines and
wellness products, it is also finding use in prescription
medicines. GW Pharmaceuticals Plc (NASDAQ: GWPH)
has created a CBD-based medicine to tackle child-onset epilepsy, a
condition that can make a normal life almost unmanageable for the
children it affects. This treatment has been approved by the FDA, making it the first cannabis
plant-based prescription medicine to be legalized by the U.S.
federal government (once the Drug Enforcement Administration
reclassifies CBD, as expected this month in response to the FDA’s
decision).
A global leader in the medical cannabis market, Tilray,
Inc. (NASDAQ: TLRY) works in research, cultivation,
processing and distribution, providing cannabis extracts and
flowers to patients, researchers and medical professionals on five
continents. As Canada prepares for growth in the cannabis market
following legalization, the company has made deals with Canadian partners to sell
its products into that market. It has also developed a CBD and THC
oil that has shown promising results in
tackling drug-resistant epilepsy.
One of the more successful companies in the cannabis sector,
Aphria, Inc. (OTC: APHQF) (TSX: APH) saw its
profits and revenues rise steadily through 2016 and
2017. Aphria recently signed a letter of intent to form a joint
venture with Perennial, Inc., in which the companies will
collaborate on developing products
for the Canadian cannabis market. Perennial’s expertise in
strategic brand development will help Aphria reach more customers
with its leading cannabis-based products, expanding its presence in
one of the world’s most important cannabis markets.
Isodiol International, Inc. (OTC: ISOLF) (CSE:
ISOL) is focused on CBD product development, with a range
of offerings that includes skin cream, pain management and help
with sleeping. It has recently expanded beyond its core products
into support for those using cannabis-derived medicines through the
creation of ISOCare. This secure platform will
help to connect patients, their family doctors and physicians
working with cannabis to ensure that patients receive the best
possible longitudinal care.
The health benefits of cannabis and its derivatives are
increasingly widely recognized. With huge potential for growth over
the next few years, CBD and cannabis are drawing customers and
companies like never before.
For more information on Marijuana Company of America, visit
Youngevity
International, Inc. (NASDAQ: YGYI)
About CannabisNewsWire
CannabisNewsWire (CNW) is an information service that provides
(1) access to our news aggregation and syndication servers, (2)
CannabisNewsBreaks that summarize
corporate news and information, (3) enhanced press release
services, (4) social media distribution and optimization services,
and (5) a full array of corporate communication solutions. As a
multifaceted financial news and content distribution company with
an extensive team of contributing journalists and writers, CNW is
uniquely positioned to best serve private and public companies that
desire to reach a wide audience of investors, consumers,
journalists and the general public. CNW has an ever-growing
distribution network of more than 5,000 key syndication outlets
across the country. By cutting through the overload of information
in today’s market, CNW brings its clients unparalleled visibility,
recognition and brand awareness. CNW is where news, content and
information converge.
Receive Text Alerts
from CannabisNewsWire: Text "Cannabis" to
21000
For more information please visit https://www.CannabisNewsWire.com and
or https://CannabisNewsWire.News
Please see full terms of use and disclaimers on the
CannabisNewsWire website applicable to all content provided by CNW,
wherever published or re-published: http://CNW.fm/Disclaimer
CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net
DISCLAIMER: CannabisNewsWire (CNW) is the source of the Article
and content set forth above. References to any issuer other than
the profiled issuer are intended solely to identify industry
participants and do not constitute an endorsement of any issuer and
do not constitute a comparison to the profiled issuer. The
commentary, views and opinions expressed in this release by CNW are
solely those of CNW. Readers of this Article and content agree that
they cannot and will not seek to hold liable CNW for any investment
decisions by their readers or subscribers. CNW is a news
dissemination and financial marketing solutions provider and is NOT
registered broker-dealers/analysts/investment advisers, hold no
investment licenses and may NOT sell, offer to sell or offer to buy
any security.
The Article and content related to the profiled company
represent the personal and subjective views of the Author, and are
subject to change at any time without notice. The information
provided in the Article and the content has been obtained from
sources which the Author believes to be reliable. However, the
Author has not independently verified or otherwise investigated all
such information. None of the Author, CNW, or any of their
respective affiliates, guarantee the accuracy or completeness of
any such information. This Article and content are not, and should
not be regarded as investment advice or as a recommendation
regarding any particular security or course of action; readers are
strongly urged to speak with their own investment advisor and
review all of the profiled issuer’s filings made with the
Securities and Exchange Commission before making any investment
decisions and should understand the risks associated with an
investment in the profiled issuer’s securities, including, but not
limited to, the complete loss of your investment.
CNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E the Securities Exchange Act of 1934, as amended and
such forward-looking statements are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. “Forward-looking statements” describe future expectations,
plans, results, or strategies and are generally preceded by words
such as “may”, “future”, “plan” or “planned”, “will” or “should”,
“expected,” “anticipates”, “draft”, “eventually” or “projected”.
You are cautioned that such statements are subject to a multitude
of risks and uncertainties that could cause future circumstances,
events, or results to differ materially from those projected in the
forward-looking statements, including the risks that actual results
may differ materially from those projected in the forward-looking
statements as a result of various factors, and other risks
identified in a company’s annual report on Form 10-K or 10-KSB and
other filings made by such company with the Securities and Exchange
Commission. You should consider these factors in evaluating the
forward-looking statements included herein, and not place undue
reliance on such statements. The forward-looking statements in this
release are made as of the date hereof and CNW undertakes no
obligation to update such statements.
Source:
CannabisNewsWire
Contact:
CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net
Isodiol (CE) (USOTC:ISOLF)
Historical Stock Chart
From Nov 2024 to Dec 2024
Isodiol (CE) (USOTC:ISOLF)
Historical Stock Chart
From Dec 2023 to Dec 2024
